Luminary Group’s Post

𝗟𝘂𝗺𝗶𝗻𝗮𝗿𝘆 𝗚𝗿𝗼𝘂𝗽, 𝗚𝗹𝗼𝗯𝗮𝗹 𝗟𝗶𝗳𝗲 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀 𝗖𝗼𝗻𝘀𝘂𝗹𝘁𝗮𝗻𝗰𝘆 #artificialintelligence #realworlddata #mergersandacquisitions #realworldevidence #productlifecycle #regulatory #pharmacovigilence #bioprocessing #cdmo #clinicaltrials #consultancy #eclinical #saas #ecoa

𝗔𝗿𝗰𝘂𝘁𝗶𝘀 𝘁𝗮𝗰𝗸𝘀 𝗼𝗻 𝗮𝘁𝗼𝗽𝗶𝗰 𝗱𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀 𝗮𝗽𝗽𝗿𝗼𝘃𝗮𝗹 𝗳𝗼𝗿 𝗭𝗼𝗿𝘆𝘃𝗲 𝗰𝗿𝗲𝗮𝗺 The FDAQRC approved Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) skin treatment Zoryve to treat mild to moderate atopic dermatitis in adults and some children, the…Frank Watanabe https://lnkd.in/dFatqhVQ

𝗩𝗖 𝗳𝗶𝗿𝗺 𝗲𝗺𝗲𝗿𝗴𝗲𝘀 𝘁𝗼 𝗯𝗼𝗼𝘀𝘁 𝗔𝘂𝘀𝘁𝗿𝗶𝗮𝗻 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝘀𝗰𝗲𝗻𝗲 𝘁𝗵𝗮𝘁’𝘀 ‘𝗿𝗲𝗮𝗱𝘆 𝘁𝗼 𝗯𝗿𝗲𝗮𝗸 𝗼𝘂𝘁’ When Christopher Trummer tried raising money for his molecular glue degrader startup, he struggled to find VC support in his native Austria …Venga Ventures, Florian Schuster https://lnkd.in/dj78yAWT

𝗪𝗵𝗲𝗻 𝗰𝗮𝗻 𝗽𝗵𝗮𝗿𝗺𝗮 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗰𝗼𝗿𝗿𝗲𝗰𝘁 𝗼𝗻𝗹𝗶𝗻𝗲 𝗺𝗶𝘀𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻? 𝗙𝗗𝗔 𝗲𝘅𝗽𝗹𝗮𝗶𝗻𝘀 The FDAQRC on Monday laid out its latest expectations for how pharma companies can correct misinformation spreading online about their medical products. The draft guidance …Robert Califf https://lnkd.in/dCXRXEzM

𝗚𝗲𝗿𝗺𝗮𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘀𝗲𝗰𝘂𝗿𝗲𝘀 €𝟲𝟯𝗠 𝗳𝗼𝗿 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗽𝗿𝗼𝗴𝗿𝗮𝗺 SciRhom has clinched €63 million ($70 million) in a Series A raise to advance its lead monoclonal antibody program through a first-in-human trial set to …Jan Poth https://lnkd.in/eeh8An7y

𝗟𝗶𝗹𝗹𝘆 𝗱𝗶𝘀𝗰𝗹𝗼𝘀𝗲𝘀 𝗶𝘁𝘀 𝗳𝗶𝗿𝘀𝘁 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿, 𝗯𝘂𝘆𝗶𝗻𝗴 𝗠𝗼𝗿𝗽𝗵𝗶𝗰 𝗳𝗼𝗿 $𝟯.𝟮𝗕 Eli Lilly and Company said Monday it plans to pay $3.2 billion in cash for Morphic Therapeutic, a biotech working on oral integrin. Praveen Tipirneni https://lnkd.in/dfb-NQVt acquisition-of-the-year-buying-morphic-for-3-2b/

𝗜𝗱𝗲𝗮𝘆𝗮 𝘀𝗵𝗼𝘄𝗰𝗮𝘀𝗲𝘀 𝗽𝗿𝗼𝗼𝗳-𝗼𝗳-𝗰𝗼𝗻𝗰𝗲𝗽𝘁 𝗱𝗮𝘁𝗮 𝗶𝗻 𝗮 𝗯𝗼𝗼𝘀𝘁 𝘁𝗼 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗹𝗲𝘁𝗵𝗮𝗹𝗶𝘁𝘆 𝗽𝗹𝗮𝘆 Fresh Phase 2 data are adding weight to Ideaya IDEAYA Biosciences case for a targeted therapy it believes could be a first-in-class treatment option for certain …Yujiro S. H. https://lnkd.in/d-wViywi

𝗖𝗶𝗿𝗰𝗹𝗲 𝗣𝗵𝗮𝗿𝗺𝗮 𝗿𝗮𝗶𝘀𝗲𝘀 $𝟱𝟰𝗠 𝗮𝘀 𝗽𝗮𝗿𝘁 𝗼𝗳 𝗦𝗲𝗿𝗶𝗲𝘀 𝗗 𝘄𝗵𝗶𝗹𝗲 𝗺𝗮𝗰𝗿𝗼𝗰𝘆𝗰𝗹𝗲𝘀 𝗵𝗲𝗮𝘁 𝘂𝗽 Circle Pharma, Inc. a startup working on macrocycles for the “undruggable,” is seeking about $117 million for a Series D. The company recently closed the first …David J. Earp, JD, PhD https://lnkd.in/dBk_adUB

𝗦𝗲𝗻𝗶𝗼𝗿 𝗧𝗮𝗹𝗲𝗻𝘁 𝗦𝗵𝗶𝗳𝘁 𝗤𝟮 𝟮𝟬𝟮𝟰 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀 In Q2 2024, there have been notable senior-level changes across the Real World Evidence, Digital Health, Consulting, and CDMO sectors. These shifts reflect the industry's ongoing evolution and the increasing demand for leaders with expertise in business transformation, strategic change, and entrepreneurial drive. In the Real World Evidence sector, new senior leaders have been appointed to spearhead efforts in leveraging real-world data for enhanced clinical and commercial insights. These changes aim to strengthen capabilities in generating robust evidence to support regulatory submissions and market access strategies in a highly competitive field, marked by fierce competition from both large corporations and smaller enterprises. 𝗨𝗦𝗔 Kyle Armbrester - CEO at Datavant Brett Kleger - CEO at Inspire Rachael Thomas Higgins - CCO at PicnicHealth Jade Cusick - CCO at Ontada Ben Stormer - CCO at Annexus Health Ryan Sloan - CGO at Galileo Jennifer M. - CGO at Lightship Lindsay Daniel - CHRO at YPrime Joshua Max Davis - SVP Commercial Operations at Ada Health Amy Eaves - BU Head Healthcare & Life Sciences at Synoptek 𝗘𝘂𝗿𝗼𝗽𝗲 Marc Funk - CEO at MARBIO Abdelaziz Toumi, PhD, MBA - CEO at Lupin Jonathan Burr - CCO at Cytel Martin Keil - VP & GM at Revvity Roberto Ascione - President at EVERSANA Pamela V. - VP HEOR, Value & Evidence at EVERSANA Jean-Christophe Massot - VP Information & Communications ProductLife Group Frédéric GAUSSENS - VP Europe & APAC PharmaLex We are excited to see how Q3 unfolds with any future senior talent shifts. If you are seeking senior-level opportunities or looking to attract senior talent, please contact our executive search team at Luminary Group. Stay tuned for the next series! #realworldevidence #rwe #rwd #regulatoryaffairs #cdmo #pharmaceutical #biotechnology

𝗝&𝗝 𝗮𝗻𝗱 𝗟𝗲𝗴𝗲𝗻𝗱 𝘀𝗮𝘆 𝗖𝗮𝗿𝘃𝘆𝗸𝘁𝗶 𝗶𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘀𝘂𝗿𝘃𝗶𝘃𝗮𝗹 𝗶𝗻 𝗲𝗮𝗿𝗹𝗶𝗲𝗿-𝗹𝗶𝗻𝗲 𝗺𝘂𝗹𝘁𝗶𝗽𝗹𝗲 𝗺𝘆𝗲𝗹𝗼𝗺𝗮 In a late-stage study, Johnson & Johnson and Legend Biotech CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three … https://lnkd.in/dfUE5XyR